Technical Analysis for ATHX - Athersys, Inc.

Grade Last Price % Change Price Change
grade F 1.43 1.42% 0.02
ATHX closed up 1.42 percent on Friday, January 18, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
5 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ATHX trend table...

Date Alert Name Type % Chg
Jan 18 Bullish Engulfing Bullish 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Oversold Stochastic Weakness 0.00%
Jan 17 New Downtrend Bearish 1.42%
Jan 17 Narrow Range Bar Range Contraction 1.42%
Jan 17 Inside Day Range Contraction 1.42%
Jan 17 Oversold Stochastic Weakness 1.42%
Jan 16 Stochastic Reached Oversold Weakness 1.42%
Jan 16 Oversold Stochastic Weakness 1.42%
Jan 14 Narrow Range Bar Range Contraction 0.70%

Older signals for ATHX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Is ATHX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Dec 17 Healios extends agreement for a license to multistem therapy for indications in China
Dec 17 Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
Dec 10 Athersys: A Lucrative China Stem Cell Licensing Deal Seems Imminent
Nov 13 Are Athersys Inc’s (NASDAQ:ATHX) Interest Costs Too High?
Nov 7 Edited Transcript of ATHX earnings conference call or presentation 6-Nov-18 9:30pm GMT
Nov 7 Athersys, Inc. (ATHX) Q3 2018 Results - Earnings Call Transcript
Nov 6 Athersys EPS in-line, beats on revenue
Nov 6 Athersys Reports Third Quarter 2018 Results
Oct 29 Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC Investment — Emerging Consolidated Expectations, Analyst Ratings
Oct 9 Athersys to Host Third Quarter Financial Results Call
See more ATHX news...
Indicators
Indicator Value
52 Week High 3.09
52 Week Low 1.29
Average Volume 584,460
200-Day Moving Average 1.993
50-Day Moving Average 1.734
20-Day Moving Average 1.4775
10-Day Moving Average 1.486
Average True Range 0.0925
ADX 25.44
+DI 13.4895
-DI 25.3865
Chandelier Exit (Long, 3 ATRs ) 1.5125
Chandelier Exit (Short, 3 ATRs ) 1.6375
Upper Bollinger Band 1.6134
Lower Bollinger Band 1.3416
Percent B (%b) 0.33
BandWidth 18.395939
MACD Line -0.0877
MACD Signal Line -0.0925
MACD Histogram 0.0048
Fundamentals Value
Market Cap 162.89 Million
Num Shares 114 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -5.50
Price-to-Sales 61.05
Price-to-Book 8.00
PEG Ratio -0.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.54
Resistance 3 (R3) 1.53 1.49 1.52
Resistance 2 (R2) 1.49 1.46 1.49 1.51
Resistance 1 (R1) 1.46 1.45 1.48 1.47 1.51
Pivot Point 1.42 1.42 1.43 1.42 1.42
Support 1 (S1) 1.39 1.39 1.41 1.40 1.35
Support 2 (S2) 1.35 1.38 1.35 1.35
Support 3 (S3) 1.32 1.35 1.34
Support 4 (S4) 1.33